NCT06394232View on ClinicalTrials.gov

Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 4, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

December 31, 2030

Conditions
Retinal DiseaseMacular DegenerationAge-Related Macular DegenerationGeographic AtrophyEye Diseases
Interventions
DRUG

Eyecyte-RPE™

Eyecyte-RPE™ is a suspension of hiPSCs (human induced Pluripotent Stem Cells) derived Retinal Pigment Epithelial Cells

Trial Locations (3)

110029

RECRUITING

All India Institute of Medical Sciences, Delhi

431203

RECRUITING

Shri Ganapati Netralaya, Jālna

500034

RECRUITING

L V Prasad Eye Institute, Hyderabad

All Listed Sponsors
lead

Eyestem Research Pvt. Ltd.

INDUSTRY